Abstract:

Objective To evaluate the efficacy and safety of reteplase in thrombolytic therapy for acute ischemic stroke. Methods Sixty-three patients with acute ischemic stroke admitted to Tai’an Hospital of Traditional Chinese Medicine were enrolled and randomly divided into the reteplase group and urokinase group. NIHSS scores, Barthel index and bleeding complications of patients in two groups before and after thrombolysis were compared. Results NIHSS scores of patients in two groups after treatment were improved significantly, the efficacy of thrombolytic drugs on patients in two groups was definite, and the difference was statistically significant at different time points (P<0.05). No significant differences in interactions of patients in two groups were found between groups and at different time points (P>0.05). The response rate of reteplase group on day 1, day 7 and day 14 after treatment was 64.5%, 77.4% and 80.6% respectively, and those of urokinase group were 31.3%, 46.9% and 53.1%, respectively. The response rate of reteplase group was higher than that of urokinase group, the response rate of patients on day 1, day 7 and day 14 was statistically significant. The comparison in Bathel index of patients in two groups showed that patients in the reteplase group had better recovery and lower disability rate (P<0.05). The cerebral hemorrhage remained to be the most serious complication, and comparative differences in haemorrhagic conditions of patients in two groups were not statistically significant. Conclusion Reteplase thrombolytic therapy delivers definite efficacy in treating acute ischemic stroke, can better improve neurological deficit function and improve the quality of life without increasing the bleeding risk.

Key words: stroke, reteplase, thrombolysis